Management of GH treatment in adult GH deficiency

Publication date: Available online 9 March 2017
Source:Best Practice & Research Clinical Endocrinology & Metabolism
Author(s): Valentina Gasco, Marina Caputo, Fabio Lanfranco, Ezio Ghigo, Silvia Grottoli
Growth hormone (GH) replacement therapy in adults with GH deficiency is still a challenge for the clinical endocrinologist and its implementation has still numerous difficulties and uncertainties. The decision to treat GH deficient adults requires a thoughtful and individualized evaluation of risks and benefits. Benefits have been found in body composition, bone health, cardiovascular risk factors, and quality of life. However, evidences for a reduction in cardiovascular events and mortality are still lacking, and treatment costs remain high.It is advisable to start treatment with low doses of GH, the goals being an appropriate clinical response, an avoidance of side effects, and IGF-I levels in the age-adjusted reference range.Although treatment appears to be overall safe, certain areas continue to require long-term surveillance, such as risks of glucose intolerance, pituitary/hypothalamic tumor recurrence, and cancer.



http://ift.tt/2mp1Uek